There’s no cure for obstructive hypertrophic cardiomyopathy (oHCM) — treatments focus on symptom management and preventing complications. But the landscape is changing, and more cutting-edge therapies are on the way.
Mavacamten (Camzyos), a cardiac myosin inhibitor and the first medication to target the underlying cause of oHCM, was approved in 2022. Now we’re on the cusp of many more therapies joining the oHCM arsenal.
“This is a hopeful time to be a patient who has limiting symptoms. People have so many more options on the table now, and so many more that are coming down the pike that are really worthwhile,” says Sara Saberi, MD, an assistant professor in the division of cardiovascular medicine at the University of Michigan in Ann Arbor.
Here’s what you may be able to expect in the next 5 to 10 years, plus what you can do to access cutting-edge oHCM treatments today.
Read the full article here
